Previous 10 | Next 10 |
New York, New York--(Newsfile Corp. - July 25, 2022) - Levi & Korsinsky, LLP notifies investors in Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) of a class action securities lawsuit. The lawsuit on behalf of Spero investors has been commenced in the the United State...
Deals and Financings Apollomics, a Foster City-Hangzhou innovative oncology biopharma, raised $100 million in a Series B financing, led by CMB International, a subsidiary of China Merchants Bank. Previously, Apollomics was known as CBT, the drug development spin-out of cancer CRO Crown Bio...
FDA meeting supports single pivotal Phase 3 clinical trial of SPR994 in cUTI SPR994 IND submitted and ADAPT-PO Phase 3 startup activities underway CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical ...
CAMBRIDGE, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections, today announced re...
CAMBRIDGE, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, announced today that Joel...
Highlights include eleven presentations covering SPR994’s pharmacokinetics and pharmacodynamics, SPR206’s broad spectrum of activity and favorable toxicology, and urinary tract infection epidemiology CAMBRIDGE, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, I...
NEW YORK, Aug. 22, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Noble Corporation (NYSE:NE), Spero Therapeutics, Inc. (NASDAQ:SPRO), AK S...
I have enough money to last me the rest of my life, unless I buy something .” ― Jackie Mason Today, we take our first look at a small ‘ Tier 4 ’ biotech concern that has only been on the market for nine months. Company Overview: Spero Therapeutics, In...
Clinical-stage biopharmaceutical firm Entasis Therapeutics has filed for an initial public offering for up to $86.25M. More news on: Tetraphase Pharmaceuticals, Shionogi & Co. Ltd. ADR, GlaxoSmithKline, Healthcare stocks news, IPOs, Read more ...
CAMBRIDGE, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, today announced the appoin...
News, Short Squeeze, Breakout and More Instantly...
Spero Therapeutics Inc. Company Name:
SPRO Stock Symbol:
NASDAQ Market:
Spero Therapeutics Inc. Website:
CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced th...
CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced t...
CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced tha...